Open AccessUpdate on the Treatment of Cervical and Uterine Carcinoma: Focus on Topotecan
Author(s) -
Fiorica James V.
Publication year - 2002
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.7-suppl_5-36
Subject(s) - medicine , topotecan , oncology , cervical cancer , radiation therapy , disease , tolerability , chemotherapy , gemcitabine , gynecology , cancer , adverse effect
L earning O bjectives After completing this course, the reader will be able to: Identify the need for new chemotherapeutic agents in the treatment of advanced gynecologic malignancies. Describe antitumor activity of topotecan in patients with advanced cervical cancer. Identify other gynecologic malignancies in which the use of topotecan is currently being explored.Access and take the CME test online and receive one hour of AMA PRA category 1 credit at CME.TheOncologist.com Carcinomas of the uterine cervix and corpus are significant causes of morbidity and mortality among women in the U.S. and are expected to contribute 10,700 deaths in 2002. Despite the widespread use of cytologic screening and improvements in early diagnosis, mortality rates have changed little over the past 25 years, and the management of cervical and uterine cancers remains a significant unmet medical need. Currently available modalities, including radiotherapy and cisplatin‐based chemotherapy, provide suboptimal control of disease, and there are no effective treatments for recurrent disease. The antitumor activity and tolerability of a number of novel agents, including topoisomerase I inhibitors, vinca alkaloids, taxanes, and gemcitabine, have been of considerable interest in treatment of these cancers. This review discusses current trends in the treatment of cervical and endometrial carcinomas, focusing on the potential role of topotecan in the treatment of non‐ovarian gynecologic malignancies.